Back to Search
Start Over
Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes
- Source :
- PR Newswire. March 29, 2022
- Publication Year :
- 2022
-
Abstract
- This study is the third ATG-016 study to be conducted in China. Study highlights Antengene's robust SINE programs. SHANGHAI and HONG KONG, March 29, 2022 /PRNewswire/ -- Antengene Corporation Limited [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PR Newswire
- Publication Type :
- News
- Accession number :
- edsgcl.698676947